Research [ASAP] Process Development and Scale-Up of RLY-2139: A Selective CDK2 Inhibitor Targeting ER+/HER2– Breast Cancer LikeLiked Date: January 24, 2026 Less than 1 MinRead Views: 59 Organic Process Research & Development DOI: 10.1021/acs.oprd.5c00342 Source: http://dx.doi.org/10.1021/acs.oprd.5c00342 Tags:Materials Industry FacebookTwitterLinkedinWhatsAppTelegramEmail ALT-Lab-Ad-1ALT-Lab-Ad-2ALT-Lab-Ad-3ALT-Lab-Ad-4ALT-Lab-Ad-5ALT-Lab-Ad-6ALT-Lab-Ad-7ALT-Lab-Ad-8ALT-Lab-Ad-9ALT-Lab-Ad-10ALT-Lab-Ad-11ALT-Lab-Ad-12ALT-Lab-Ad-13 Recent Articles Integrating transdisciplinary social-hydrology and value addition for sustainable spring-fed water management in the Anthropocene: Insights from the Central Himalaya Research November 16, 2026 Research November 16, 2026 Land use practices for net-zero: an overview Research November 15, 2026 Mapped: Where Teenage Birth Rates Are Highest Finance & investments November 15, 2026 Warm weather and dry conditions help Ontario farmers advance harvest Food & Agriculture November 15, 2026 Ranked: The Everyday Skills Men and Women Say They Have Finance & investments November 15, 2026 Bioactive-compound-rich liquid products from full-scale alkaline thermal hydrolysis of municipal sewage sludge: agronomic performance and metabolic responses of lettuce Research November 15, 2026 Conceptualizing a building passport: defining its scope and requirements through a Delphi study Research November 15, 2026 As Texas embraces carbon storage, a Black community questions the risks Energy November 15, 2026 Ranked: The Countries That Drink the Most Wine Finance & investments November 15, 2026 Load more